Antioxidant Properties of Galantamine Hydrobromide

Traykova, Maria; Traykov, T.; Hadjimitova, Vera; Krikorian, KrikorS.; Bojadgieva, N

doi:10.1515/znc-2003-5-613

Cited by 42 publications

(25 citation statements)

References 1 publication

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Considering that the first administration of the drug in this protocol was not until 3 h after ischemia, galantamine could be protecting against the cell death caused by oxygen radicals generated during the reperfusion period. In fact, galantamine is a molecule with antioxidant properties (Traykova et al, 2003). It is well documented that reperfusion after brain ischemia triggers the overproduction of reactive oxygen species that can exacerbate cell death (McCord, 1985).…”

Section: Discussionmentioning

confidence: 99%

Galantamine Postischemia Provides Neuroprotection and Memory Recovery against Transient Global Cerebral Ischemia in Gerbils

Lorrio¹,

Sobrado²,

Arias³

et al. 2007

J Pharmacol Exp Ther

View full text Add to dashboard Cite

Galantamine, currently used in Alzheimer's patients, has shown neuroprotection in hippocampal slices subjected to oxygenglucose deprivation. Here, we present an in vivo study to evaluate the potential neuroprotective effects of galantamine in a transient global cerebral ischemia model in gerbils. Three treatment protocols were used. In the pretreatment protocol, gerbils were treated before ischemia and for 3 consecutive days thereafter. Eight groups of animals were included: sham operation plus placebo, 10 mg/kg mecamylamine and 10 mg/kg galantamine, respectively; and ischemia plus placebo, 10 mg/kg mecamylamine, 1 mg/kg galantamine, and 10 mg/kg galantamine and 10 mg/kg mecamylamine plus galantamine, respectively. Postischemia protocols included three groups of animals: sham operation, ischemia plus placebo, and ischemia plus 10 mg/kg galantamine; substances were administered 3 or 6 h after ischemia and for 2 consecutive days thereafter. Pyramidal neurons surviving in the cornus ammonis 1 region of the hippocampus were evaluated 72 h after reperfusion, terminal deoxynucleotidyl transferase dUTP nick-end labeling (TUNEL) histochemistry, caspase-3 and superoxide dismutase (SOD)-2 immunohistochemistries, and Western blottings were performed, and object placement tests were carried out. Galantamine significantly increased the number of living pyramidal neurons after ischemia-reperfusion injury. Galantamine significantly reduced TUNEL, active caspase-3, and SOD-2 immunoreactivity. The nicotinic antagonist mecamylamine blocked the protective effects of galantamine. The neuroprotective effects of galantamine were preserved even when first administered at 3 h postischemia. These results correlated with the performance in the object placement test. This study shows that galantamine provides in vivo neuroprotection and memory recovery against global cerebral ischemia, even when administration begins 3 h postischemia.

show abstract

Section: Discussionmentioning

confidence: 99%

Galantamine Postischemia Provides Neuroprotection and Memory Recovery against Transient Global Cerebral Ischemia in Gerbils

Lorrio¹,

Sobrado²,

Arias³

et al. 2007

J Pharmacol Exp Ther

View full text Add to dashboard Cite

show abstract

“…According to Traykova et al 31 , the FT-IR spectrum of GH is very characteristic. It shows several bands, of which the most characteristic are: the stretching O-H bond vibration of the enol group (C ¼ C-O-H) at 3559 cm À1 and the band which results from overlapping of the stretching vibration of physically adsorbed hydrogen bonded water and hydrogen bonded N-H Figure 2.…”

Section: Ft-ir Spectrometrymentioning

confidence: 99%

Complexation as an approach to entrap cationic drugs into cationic nanoparticles administered intranasally for Alzheimer's disease management: preparation and detection in rat brain

Hanafy

Farid

El-Gamal

2015

Drug Development and Industrial Pharmacy

104

View full text Add to dashboard Cite

show abstract

“…The multiple neuroprotective effects of melatonin, which include its anti-apoptotic, anti-inflammatory, and antioxidant actions, are mediated by both receptor and nonreceptor pathways. On the other hand, it has been demonstrated that the neuroprotective effect of galantamine, a wellknown AChEI used to treat AD, is associated to its ability to act on nicotinic receptors [28] and to its antioxidant effect [38]. Hence, both drugs could be good candidates to combat AD.…”

Section: Discussionmentioning

confidence: 99%

Subthreshold Concentrations of Melatonin and Galantamine Improves Pathological AD-Hallmarks in Hippocampal Organotypic Cultures

et al. 2015

View full text Add to dashboard Cite

Melatonin is a neurohormone whose levels are significantly reduced or absent in Alzheimer's disease (AD) patients. In these patients, acetylcholinesterase inhibitors (AChEI) are the major drug class used for their treatment; however, they present unwanted cholinergic side effects and have provided limited efficacy in clinic. Because combination therapy is being extensively used to treat different pathological diseases such as cancer or acquired immune deficiency syndrome, we posed this study to evaluate if melatonin in combination with an AChEI, galantamine, could provide beneficial properties in a novel in vitro model of AD. Thus, we subjected organotypic hippocampal cultures (OHCs) to subtoxic concentrations of β-amyloid (0.5 μM βA) plus okadaic acid (1 nM OA), for 4 days. This treatment increased by 95 % cell death, which was mainly apoptotic as shown by positive TUNEL staining. In addition, the combination of βA/OA increased Thioflavin S aggregates, hyperphosphorylation of Tau, oxidative stress (increased DCFDA fluorescence), and neuroinflammation (increased IL-1β and TNFα). Under these experimental conditions, melatonin (1-1000 nM) and galantamine (10-1000 nM), co-incubated with the toxic stimuli, caused a concentration-dependent neuroprotection; maximal neuroprotective effect was achieved at 1 μM of melatonin and galantamine. Most effective was the finding that combination of sub-effective concentrations of melatonin (1 nM) and galantamine (10 nM) provided a synergic anti-apoptotic effect and reduction of most of the AD-related pathological hallmarks observed in the βA/OA model. Therefore, we suggest that supplementation of melatonin in combination with lower doses of AChEIs could be an interesting strategy for AD patients.

show abstract

Antioxidant Properties of Galantamine Hydrobromide

Cited by 42 publications

References 1 publication

Galantamine Postischemia Provides Neuroprotection and Memory Recovery against Transient Global Cerebral Ischemia in Gerbils

Galantamine Postischemia Provides Neuroprotection and Memory Recovery against Transient Global Cerebral Ischemia in Gerbils

Complexation as an approach to entrap cationic drugs into cationic nanoparticles administered intranasally for Alzheimer's disease management: preparation and detection in rat brain

Subthreshold Concentrations of Melatonin and Galantamine Improves Pathological AD-Hallmarks in Hippocampal Organotypic Cultures

Contact Info

Product

Resources

About